Genoptix Ranked 15th Fastest-Growing Company in North America on Deloitte's 2009 Technology Fast 500(TM)

CARLSBAD, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced that it ranked number 15 on Technology Fast 500(TM), Deloitte LLP's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2004-2008. Genoptix grew 15,814 percent during this period.

"We are honored to rank among the top 20 fastest-growing technology companies in North America for the second year in a row," said Tina S. Nova, Ph.D., President and CEO of Genoptix, which last year was ranked number nine on the Technology Fast 500. "Our specialized, physician-directed approach to testing and diagnosis continues to drive increasing demand for our services nationwide. We have grown rapidly by focusing on the needs of community-based hematologists and oncologists, and this recognition is a testament to the exceptional execution of the entire Genoptix team."

In addition, Genoptix was ranked the second fastest-growing company in the San Diego region, according to the Technology Fast 500. Genoptix reported revenues of $116.2 million, $59.3 million, $24.0 million, $5.2 million, and $0.7 million in 2008, 2007, 2006, 2005 and 2004, respectively. In the second quarter of 2009, the company managed more than 14,200 patient cases and serviced approximately 1,250 community based hematologists and oncologists across the country during the month of June. Genoptix had 360 employees as of June 30, 2009.

"Technology Fast 500(TM) recognizes innovative companies that have broken down barriers to success and defied the odds with their remarkable five-year revenue growth," said Phil Asmundson, Vice Chairman and U.S. Technology, Media and Telecommunications leader, Deloitte LLP. "We congratulate Genoptix on this accomplishment."

Technology Fast 500(TM) Selection and Qualifying Criteria

Technology Fast 500(TM) provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500(TM) website, and public company database research conducted by Deloitte. Technology Fast 500(TM) award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.

In order to be eligible for Technology Fast 500(TM) recognition, companies must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues. Using other companies' technology or intellectual property in a unique way does not satisfy this requirement. Consulting companies, professional service firms, etc. are not eligible unless they have proprietary technology that contributes to a significant portion of their operating revenues.

Technology Fast 500(TM) award eligibility requirements also include base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. These revenues must have more than doubled between 2004 and 2008. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

About Deloitte

As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Genoptix, Inc.